After three decades of no new…
After three decades of no new antibiotics for the treatment [...]
After three decades of no new antibiotics for the treatment [...]
The CDC findings were released as the FDA considers placing [...]
GSK’s depemokimab, a long-acting biologic that’s key to the British [...]
As it shifts strategic direction to prioritize its recently acquired [...]
After a year marked by dramatic ups and downs, William [...]
Zealand Pharma may be gearing up for a high-stakes year [...]
Thursday, the FDA greenlighted Uplizna to treat generalized myasthenia gravis [...]
With an increase in the antimicrobial resistance to therapies for [...]
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT [...]
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare [...]